{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:45:40Z","timestamp":1789062340305,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Minhang Hospital, Fudan University - Prostatic Cancer Center","award":["YJXK-2021-18"],"award-info":[{"award-number":["YJXK-2021-18"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To investigate the efficacy and safety of docetaxel chemotherapy combined with androgen-deprivation therapy for patients with high-volume disease metastatic hormone-sensitive prostate cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>153 cases of high-volume disease metastatic hormone-sensitive prostate cancer in Minhang Hospital between January 2018 and December 2019 were analyzed retrospectively, including the number of patients, age, initial PSA level, Gleason score, TNM stage and ECOG score. 90 patients in the endocrine therapy group received continuous ADT, and 63 patients in the combined chemotherapy group received docetaxel plus ADT. The progression-free survival time (time from initiation of prostate cancer treatment to progression to CRPC), PSA response rate, and adverse reactions were compared between the two groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All 153 cases were closely followed up for a period of 12.3\u201335.3\u00a0months, with a median follow-up time of 23.5\u00a0months. The median time to reach the lowest point of PSA in the two groups was 6.3\u00a0months and 7.9\u00a0months (<jats:italic>P<\/jats:italic>\u2009=\u20090.018) in the combination chemotherapy group and the ADT group alone, with 27 (42.9%) and 12 (13.3%) cases in the two groups Within 12\u00a0months of treatment, PSA decreased to below 0.2\u00a0ng\/ml (<jats:italic>P<\/jats:italic>\u2009=\u20090.02), and progression-free survival was 16.9\u00a0months (6.5\u201328.5\u00a0months) and 11.2\u00a0months (4.3\u201322.7\u00a0months) in the two groups. (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). There were 18 cases (28.6%) and 54 cases (60%) in the two groups with disease progression (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). There were 6 cases (9.5%) and 15 cases (16.7%) in the combination chemotherapy group and the ADT group died of prostate cancer and related complications, respectively. All 63 cases in the combined chemotherapy group completed 6 cycles of chemotherapy. 39 (61.9%) cases experienced varying degrees of neutropenia, of which 12 (19%) experienced grade 3\u20134 neutropenia, with 6 cases (9.5%) developed febrile neutropenia. 30 cases (47.6%) had toxic reactions in the digestive system, and 3 case (4.3%) had grade 3 liver dysfunction. 27 cases (42.8%) had skin and mucosal toxicity. 9 cases (14.3%) had mild fluid retention. No blood and digestive toxicity were observed in the ADT group. 33 cases (52.4%) and 48 (53.3%) of the two groups had symptoms of afternoon hot flashes and fatigue, (<jats:italic>P<\/jats:italic>\u2009=\u20090.961).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Docetaxel chemotherapy combined with endocrine therapy could be one of effective treatments for delaying castration resistance of HVD-mHSPC, which could prolong PFS effectively and obtain a higher PSA response rate, high safety under close monitoring, and controllable adverse reactions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-022-00773-1","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T11:06:39Z","timestamp":1660215999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis"],"prefix":"10.1186","volume":"27","author":[{"given":"Zhuifeng","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuwei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"issue":"3","key":"773_CR1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"773_CR2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"773_CR3","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/JU.0000000000001313","volume":"204","author":"M Maggi","year":"2020","unstructured":"Maggi M, et al. The long-term risks of metastases in men on active surveillance for early stage prostate cancer. J Urol. 2020;204(6):1222\u20138.","journal-title":"J Urol"},{"issue":"6","key":"773_CR4","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/j.juro.2013.06.017","volume":"190","author":"RJ Karnes","year":"2013","unstructured":"Karnes RJ, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol. 2013;190(6):2047\u201353.","journal-title":"J Urol"},{"issue":"10024","key":"773_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163\u201377.","journal-title":"Lancet"},{"issue":"8","key":"773_CR6","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737\u201346.","journal-title":"N Engl J Med"},{"issue":"2","key":"773_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/bju.14025","volume":"121","author":"RJ Rulach","year":"2018","unstructured":"Rulach RJ, et al. Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU Int. 2018;121(2):268\u201374.","journal-title":"BJU Int"},{"issue":"3","key":"773_CR8","first-page":"161","volume":"38","author":"Urology Branch of Chinese Medical Association, C.P.C.A.","year":"2017","unstructured":"Urology Branch of Chinese Medical Association, C.P.C.A. Chinese expert consensus on chemotherapy of metastatic prostate cancer (2017 Edition). Chin J Urol. 2017;38(3):161\u20135.","journal-title":"Chin J Urol"},{"issue":"6","key":"773_CR9","first-page":"418","volume":"57","author":"P Xu","year":"2019","unstructured":"Xu P, Shen Y, Wenjun Xia, Guowen Lin, Xiaojian Qin, Yao Zhu, et al. Short-term efficacy and adverse reactions of endocrine therapy combined with chemotherapy for metastatic hormone-sensitive prostate cancer with high tumor load. Chin J Surg. 2019;57(6):418\u201321.","journal-title":"Chin J Surg."},{"issue":"10013","key":"773_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","volume":"387","author":"G Attard","year":"2016","unstructured":"Attard G, et al. Prostate cancer. Lancet. 2016;387(10013):70\u201382.","journal-title":"Lancet"},{"issue":"2","key":"773_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149\u201358.","journal-title":"Lancet Oncol"},{"issue":"2","key":"773_CR12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"G Gravis","year":"2016","unstructured":"Gravis G, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70(2):256\u201362.","journal-title":"Eur Urol"},{"issue":"11","key":"773_CR13","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"773_CR14","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","volume":"36","author":"LC Harshman","year":"2018","unstructured":"Harshman LC, et al. Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel. J Clin Oncol. 2018;36(4):376\u201382.","journal-title":"J Clin Oncol"},{"issue":"1","key":"773_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejon.2008.10.003","volume":"13","author":"J Baker","year":"2009","unstructured":"Baker J, et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2009;13(1):49\u201359.","journal-title":"Eur J Oncol Nurs"},{"issue":"4","key":"773_CR16","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.juro.2014.11.006","volume":"193","author":"AK Morgans","year":"2015","unstructured":"Morgans AK, et al. Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy. J Urol. 2015;193(4):1226\u201331.","journal-title":"J Urol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-022-00773-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T11:08:02Z","timestamp":1660216082000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-022-00773-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["773"],"URL":"https:\/\/doi.org\/10.1186\/s40001-022-00773-1","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]},"assertion":[{"value":"25 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval to report this case was obtained from Ethics committee of Minhang Hospital Affiliated to Fudan University (2018-the certificate-032-01\u00a0K). Written informed consent was obtained from the patient(s) for their anonymized information to be published in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of their clinical details and\/or clinical images was obtained from the patient\/guardian\/relative of the patient. The findings of the study will be published in peer-reviewed journals and presented at national and international scientific meetings.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}